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Introduction 
 
Lafora disease is an autosomal recessive, progressive myoclonus epilepsy that 
causes neurodegeneration, dementia and death[1, 2]. Affected individuals have an initial 
seizure around the age of 12 followed by severe neurological deterioration until the 
patient’s death about ten years after the initial seizure[1, 3]. Biopsies of various tissues, 
including muscle, liver, and brain, reveal the abnormal intracellular buildup of insoluble 
glycogen-like particles, called Lafora bodies[1, 4]. Over 50% of Lafora disease cases are 
caused by mutations in the gene coding for the protein laforin[3-5]. 
Laforin is a bimodular protein with a carbohydrate-binding module (CBM) and a 
phosphatase domain (Figure 1A)[6-8]. Phosphatases typically remove a phosphate group 
from proteins (i.e dephosphorylate). Phosphatases oppose the action of kinases, which 
phosphorylate proteins. Phosphorylation and dephosphorylation events cause structural 
changes within the protein that can: 1) turn the protein’s enzymatic activity off or on, 2) 
increase or decrease the proteins’ binding to another protein, 3) initiate other events. 
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Figure 1A. Laforin has an N-terminal CBM and a C-terminal 
phosphatase domain. B. Percent similarity and identity between 
full length human laforin and other laforin orthologs. C. An 
amino acid sequence alignment across five species. Dark grey 
indicates highly conserved residues, while similar residues are in 
light grey. Resides in red boxes are invariant residues as defined 
by the CBM20 family; blue boxes indicate residues that are part 
of the phosphatase catalytic site. Predicted secondary structure is 
also shown (ovals represent α-helices and arrows indicate β- 
sheets). 
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Figure 2. A. Glycogen is a polymer 
of glucose with mostly α-1,4 
linkages and α-1,6 linkages at 
branch points. B. The complex, 
branched structure of glycogen 
renders the molecule water-soluble. 
C. Lafora bodies can be observed in 
most tissues of patients with Lafora 
disease. Errors in glycogen 
metabolism may cause the 
formation of Lafora bodies. 
 
 
Laforin is unique among phosphatases in that it is the only phosphatase in humans that 
contains a CBM[9].  The CBM of laforin allows it to bind glycogen so that the 
phosphatase domain can remove phosphate from glycogen[10]. Thus, laforin 
dephosphorylates carbohydrates (i.e. glycogen) instead of a protein. 
Glycogen is an energy storage molecule synthesized by bacterial, fungal and 
animal species consisting of α-1,4 and α-1,6 linked residues of glucose, with around 12- 
14 residues per branch. Because of this pattern of branching, glycogen is water soluble 
(Figure 2A, B). During the formation of glycogen, UDP-glucose is added to the growing 
glycogen molecule by the enzyme glycogen synthase, and the phosphate is removed. 
However, recent evidence shows that glycogen synthase occasionally makes a mistake 
and incorporates the phosphate from UDP into glycogen approximately every 10,000 
glucose residues[11]. Thus, the glycogen polymer contains some phosphate. 
Laforin is needed to remove these phosphate groups during the formation of 
glycogen because the phosphate groups inhibit the normal branching of glycogen[10, 12]. 
When the gene for laforin is mutated and laforin activity is lost, glycogen is inundated 
with phosphate, inhibiting the action of enzymes that orchestrate glycogen branching. 
The hyperphosphorylated glycogen results in a Lafora body (LB) [1]. Like glycogen, LBs 
are made of α-1,4 and α-1,6 linked residues of glucose, but the branches are much longer 
in LBs. The longer branches cause LBs to be water insoluble (Figure 2C). In neurons, 
LBs cause apoptosis (i.e. cell death). This may occur because neurons store little energy 
and depend highly on glycogen from other cells, so if glucose gets “trapped” in LBs, the 
cell dies[13]. It is also possible that LBs create trafficking problems in the cell[13]. 
Although the exact mechanism of neuronal apoptosis is not known, it is clear that in the 
absence of laforin LBs form and the result is Lafora disease. 
Mutations in either domain of laforin can lead to Lafora disease. Many of these 
mutations affect amino acids that are highly conserved and essential to carbohydrate- 
binding or phosphatase activity[5]. However, a three-dimensional analysis is necessary to 
understand the structural basis of laforin’s function. We aim to determine the structure of 
laforin using X-ray crystallography. This is a cutting-edge technique that uses scattered 
X-rays to generate the complete atomic structure of a protein[14]. The protein of interest 
is grown as a densely packed crystal similar to a crystal of table salt, and then exposed to 
a high-powered beam of X-rays. These X-rays produce a diffraction pattern that can be 
transformed into a three-dimensional image of the protein. Part of this project has been to 
optimize expression of recombinant laforin to utilize in protein crystallization trials. 
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Another issue that this work has addressed is a recent claim from other groups that 
laforin is mainly present as a dimer (i.e. two single units, called monomers, bound 
together) and that dimerization is critical for its phosphatase activity[15, 16]. However, 
our lab and others see that the monomeric and dimeric species have equal phosphatase and 
starch-binding activity and that dimerization interferes with its ability to interact with 
other proteins[17]. To address this specific experiments were performed to test if laforin 
is functionally relevant as a monomer. 
A key problem with studying laforin has been the inability to purify sufficient 
quantities of pure laforin protein[15]. Bacterial cells are often employed to produce 
recombinant human proteins, since they offer an affordable platform for protein 
production. However, not all proteins are easily produced using this system. Inclusion 
bodies, masses of insoluble protein that is often incorrectly folded, may result when a 
protein is expressed in a foreign environment. A possible cause of this is the lack of 
eukaryotic post-translational mechanisms in bacterial cells; however, even overexpressed 
E. coli proteins are often difficult to produce in soluble form in their native host[18]. An 
alternate method is to purify the target protein from inclusion bodies. One group recently 
published that human laforin is sequestered into inclusion bodies, and must be purified out 
of them[15]. This procedure requires denaturation and refolding steps, involves harsh 
chemical treatments, and often yields low amounts of correctly-folded protein, which is 
useless for biochemical experimentation. Therefore, purification of soluble, natively 
folded protein is preferable. 
To circumvent the issues surrounding inclusion body sequestration and 
purification, labs often clone the gene encoding their protein of interest from several 
organisms (i.e. orthologous genes), and test the expression of each of these genes in 
bacteria. Sometimes the same protein from a different organism will express differently 
in bacteria (i.e. one may be inside inclusion bodies and another will fold correctly). Homo 
sapien (human) laforin shares marked similarity with Gallus gallus (chicken), Xenopus 
tropicalis (frog), Anolis carolinensis (lizard) and Danio rerio (zebrafish) laforin 
orthologues. Gallus gallus laforin and human laforin are 84% similar and 73% identical, 
meaning 84% of amino acids that make up the proteins are chemically similar and 73% 
of amino acids are exactly the same in both species (Figure 1A). Functionally significant 
amino acid residues are highly conserved in the four species (Figure 1B, C). Therefore, 
any information we gain about another animal laforin will be directly applicable to 
human laforin and Lafora disease. 
 
Overview of Methods 
 
In this project, the gene for laforin from the Gallus gallus (Gg) genome had 
previously been cloned into a plasmid engineered to express genes in bacteria, called a 
vector. Gg-laforin was inserted into a vector containing the coding sequence for a 
hexahistidine (HIS6-) and SUMO-tag. These fusion tags are attached to the N-terminus of 
the protein during expression and allow the protein to be purified from the bacterial cell 
lysate by immobilized metal affinity chromatography (IMAC). In this process the HIS6- 
tag binds to a column of immobilized nickel ions, while other proteins pass over the 
column. Thus, these tags act like a hook to grab hold of the target protein. 
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After this first step, these fusion tags are 
removed by a Ubiquitin-like-specific protease 1 
also containing a HIS6 tag (HIS6-ULP1), which is 
an enzyme that targets and cleaves the HIS6- 
SUMO-tag from the laforin protein. This cleavage 
is  necessary  because  the  HIS6-SUMO-tag  (14 
kDa, compared to 36 kDa, the size of laforin) may 
affect the structure and function of laforin. For 
precise crystallography studies, laforin must be 
free from large fusion tags. Another round of 
affinity  chromatography  was  employed  to 
separate the cleaved tag from the laforin protein. 
Figure 3 shows each step of the purification 
process. 
To determine whether laforin is present as 
a monomer or a dimer, we used a technique called 
size-exclusion chromatography. The solution 
containing the protein is passed through a column 
of porous material, allowing particles in solution 
to be separated according to their size (Figure 4). 
Larger  particles  do  not  penetrate  the  smallest 
pores in the column and are eluted first, while 
smaller particles become wedged in the pores and 
move  through  the  column  more  slowly.  The 
laforin  dimer  (72  kDa),  twice  the  size  of  the 
laforin monomer, would elute first, and the 
monomer later. To determine if the monomer 
converts to a dimer, the fractions containing the 
monomer were combined and put back over the 
column; a single peak on the chromatogram 
indicates that the monomer remains monomeric. 
Laforin was also analyzed using dynamic 
light scattering (DLS) and mass spectrometry. In 
DLS, the scattering of light is used to determine 
the radius of small molecules in solution. Particles 
in solution undergo Brownian motion and diffuse 
at   a   rate   depending   on   their   size   (smaller 
molecules diffuse more rapidly than larger 
molecules). When light is scattered by these 
moving  particles,  the  intensity  of  the  scattered 
light correlates to the rate of diffusion of the 
particles.   One can calculate the radius of a 
molecule using this rate of diffusion, called the 
“hydrodynamic radius”[19]. Hydrodynamic radius 
is used to estimate protein size using a standard 
curve of known proteins. Because proteins are not 
 
 
Figure 3. Purification scheme for 
Gg-laforin involving expression in 
E. coli, multiple chromatography 
steps, and various protein analysis 
techniques. 
 
 
 
 
Figure 4. A schematic of size-exclusion 
chromatography, showing how this 
technique separates proteins according to 
size. 
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perfectly  spherical,  hydrodynamic  size  is  a  rough  estimate  of  actual  protein  size; 
however, with this technique we can distinguish small oligomers, i.e. whether a protein is 
a monomer or dimer. Both DLS and mass spectrometry were used to determine the size 
of laforin and confirm the results obtained by size-exclusion chromatography. 
Once these chromatography steps were complete, the phosphatase activity of Gg- 
laforin was characterized and compared to human laforin using two assays. In the first 
assay, the artificial substrate para-nitrophenyl phosphate (pNPP) is converted to para- 
nitrophenol when phosphate is removed. This produces a bright yellow color in alkaline 
conditions. A spectrophotometer is used to measure this color change, which corresponds 
to the activity of the phosphatase (Figure 5A). The pNPP assay is useful for quickly 
quanitifying the activity of phosphatases. Since laforin has been shown to 
dephosphorylate carbohydrates, a more physiologically relevant assay that we employ is 
the malachite green assay. This assay involves the reaction of a malachite green reagent 
with liberated phosphate to produce a colorimetric change, which again is measured. 
Phosphorylated amylopectin was used as the substrate for laforin because amylopectin is 
more similar to the endogenous substrate glycogen than pNPP. Color change is again 
used to quantify phosphatase activity (Figure 5B). 
Laforin has been shown to bind carbohydrates, including glycogen and the 
components of plant starch, amylose and amylopectin. We developed an assay to test Gg- 
 
A. C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic of the pNPP reaction (A), in which an artificial substrate is dephosphorylated and 
produces a color change, malachite green assay (B), which uses amylopectin as a substrate, and glucan 
binding assay (C). 
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laforin for starch-binding using amylose immobilized on agarose beads. The enzyme is 
incubated with amylose beads for thirty minutes, and then the solution is centrifuged to 
separate the pellet from the supernatant (Figure 5C). Any protein that is bound to the 
amylose will remain in the pellet, and any protein that does not bind the amylose is 
present in the supernatant. The supernatant is collected, and the pellet is resuspended in a 
buffer that denatures and detaches any protein bound to the beads. These two fractions 
are then analyzed by SDS-PAGE and Western blotting. 
Phosphatase activity levels and carbohydrate-binding that are similar to those of 
human laforin would indicate that Gg-laforin is active as a monomer, possesses the same 
biochemical characteristics as human laforin, and can be used to model human laforin in 
future crystallographic analysis. 
 
 
 
Materials and Methods 
 
Cloning procedures 
The plasmid ppSUMO was a generous gift from Dr. Jack Dixon (University of 
Calfornia, San Diego, USA). 
An expressed sequence tag (EST) of Gg-laforin was purchased from Delaware 
Biotechnology Institute and cloned into ppSUMO according to standard protocols. The 
Gg-laforin sequence was inserted into BamHI/XhoI sites of ppSUMO. ppSUMO encodes 
a small Ub-like modifier (SUMO) fusion tag that includes an amino-terminal HIS6 
sequence to aid purification. Construct sequence was verified by DNA sequencing. 
Escherichia coli DH5α cells were transformed with ppSUMO Gg-laforin construct. Gg- 
laforin point mutations were introduced using QuikChange Site-Directed Mutagenesis kit 
(Stratagene) according to manufacturer’s instructions. pET21a Vaccinia H1-related 
phosphatase (VHR) and pET21a Hs-laforin constructs have been described previously[9]. 
 
Expression and Purification 
Gg-laforin was expressed as a HIS6-SUMO fusion protein in BL21-CodonPlus 
Escherichia coli cells (Stratagene) and purified using immobilized metal affinity 
chromatography and size-exclusion chromatography as described previously[9, 17, 20]. 
Bacterial cultures were grown in 1L Terrific Broth (IBI Scientific) with 1 mM 
kanamyacin and 1 mM chloramphenicol at 37°C until OD600 reached ~0.8. Cultures were 
chilled on ice for 20 minutes, and isopropyl thio-β-D-galactopyranoside (IPTG) was 
added for a final concentration of 1 mM to induce protein expression. After growth for 
approximately 12-16 hours at room temperature, cells were harvested by centrifugation 
and stored at -20°C. Bacterial pellets were resuspended in 20mM Tris/HCl (pH 7.5), 
100mM NaCl and 2 mM dithiothreitol (DTT). HIS6-SUMO-Gg-laforin was purified 
using a Profinia IMAC column (Bio-Rad) with a Profinia protein purification system 
(Bio-Rad), dialyzed into 20mM Tris/HCl (pH 7.5), 100mM NaCl and 2 mM DTT in the 
presence of the SUMO-specific protease ULP1 that also contains a HIS6-tag. Reverse 
purification over the Profinia IMAC column was used to remove ULP1 and the fusion 
tag. The protein was then purified using a HiLoad 16/60 Superdex 200 size-exclusion 
column and ÄKTA FPLC (GE Healthcare). Fractions containing the monomer species 
were collected, put back over the same column, and then again over a Superdex 75 
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column (GE Healthcare). VHR and Hs-laforin were also expressed as HIS6-tagged 
recombinant proteins and purified in a similar manner. 
 
Protein gel electrophoresis, dynamic light scattering and mass spectrometry 
Protein purity was assessed by denaturing gel electrophoresis using NuPAGE 
10% Bis-Tris gels (Invitrogen). Gels were stained with Coomassie brilliant blue to 
visualize proteins. Dynamic light scattering (Protein Solutions DynaPro-99) was utilized 
to determine the hydrodynamic radius of particles in solution. A standard curve was used 
to calculate the approximate size of a globular protein with the measured hydrodynamic 
radius. Measurements were performed on a protein sample of 1 mg/ml at room 
temperature. We utilized matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry to analyze purified protein. 
 
Starch-binding assay 
Recombinant HIS6-tagged proteins were incubated with 30 µl amylose 
immobilized on agarose resin (New England Biolabs). Amylose beads was pre-incubated 
with 1% BSA at room temperature for 30 min to prevent nonspecific binding. 0.25-5 µg 
protein was mixed with amylose beads in 20mM Tris/HCl (pH 7.5), 100 mM NaCl, 2 
mM DTT and 1 × protease inhibitor cocktail (2.5 mM AEBSF, 2.5 mM benzamidine 
hydrochloride, 2.5 µM leupeptin, 2.5 µM E64), rotating at 4°C for 30 min. Amylose 
beads were pelleted by centrifugation, supernatant was removed, proteins in supernatant 
were precipitated, and proteins in the pellet and supernatant were visualized by Western 
analysis. Blots were probed with mouse anti-His 1:4000 (NeuroMabs) and goat anti- 
mouse HRP (Invitrogen). SuperSignal West Pico (Thermo Scientific) was used to detect 
the HRP signal. 
 
Phosphatase assays 
Phosphatase activity was determined using the substrates para- 
nitrophenylphosphate (pNPP) and potato amylopectin as described previously[9, 17]. The 
pNPP reactions were carried out in 50µl reactions in 1 × phosphate buffer (0.1 M sodium 
acetate, 0.05 M bis-Tris, 0.05 M Tris-HCl, and 2 mM DTT at the appropriate pH), 50 
mM pNPP, and 200-400 µg enzyme at 37°C for 2 min. Reactions were terminated with 
the addition of 200 µl 0.25 M NaOH. Absorbance was measured at 410 nm. Malachite 
green reactions were carried out in 20 µl reactions in 1 × phosphate buffer, 45µg 
amylopectin, and 100 ng enzyme at 37°C. After 2-5 minutes, 20 µl 0.1 M N- 
ethylmalemide and 80 µl malachite green reagent was added to quench the reaction and 
absorbances were measured at 620 nm after 40 minutes. Assays were performed in 
triplicate for each enzyme at pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0. 
 
Sequence Alignment 
Amino acid sequences of laforin orthologues were aligned by PROMALS3D structure 
alignment server[21] and displayed in MacVector. 
8  
Results and Discussion 
 
Gg-laforin purification 
Recombinant Gg-laforin was expressed and purified from E. coli by affinity 
chromatography, digested with ULP1, and subjected to reverse affinity chromatography 
to remove the fusion tag and ULP1. These steps yielded 9.8 mg of untagged Gg-laforin 
per liter of bacterial culture. Gg-laforin was then passed over a Superdex 16/60 S200 
size-exclusion column and resolved into multiple prominent and separate peaks. The 
initial peak was likely composed of unresolved Gg-laforin oligomers. Dimer and 
monomer fractions are labeled, and the monomer peak contained 1.2 mg of protein (Fig. 
6A). It is possible that laforin exists in a dynamic oligomeric state, dissociating between a 
monomer and a dimer. To test this, we collected the fractions from the monomer peak, 
concentrated them, and passed these fractions over the same column. No dimer peak was 
present during this second run, suggesting that the monomer species is the dominant 
species (Fig. 6B). The protein content and purity was determined by collecting fractions 
from the purification steps and analyzing them by SDS-PAGE. The expected size of Gg- 
laforin is 36 kDa and a single 36 kDa band was easily visible in the final purification lane 
of the gel (Fig. 6C). 
After purification, the S200 purified Gg-laforin was analyzed using dynamic light 
scattering (DLS). The hydrodynamic radius of the detected species corresponded to a 
31.6 ±14.5 kDa globular protein. This molecular weight is the approximate size of the 
laforin monomer (Fig. 6D).  To further test the molecular weight of the Gg-laforin 
species, we analyzed the final purified fraction using mass spectrometry. This analysis 
also confirmed the presence of a single species with a molecular weight of 36 kDa. 
 
Gg-laforin monomer binds carbohydrates 
The CBM of Hs-laforin distinguishes this phosphatase from others in that it 
enables human laforin to bind carbohydrates. Gg-laforin is predicted to also bind 
carbohydrates via its CBM. We investigated the starch-binding properties of Gg-laforin 
using amylose attached to agarose beads. Hs-laforin was used as a positive control and 
VHR, a phosphatase incapable of binding carbohydrates due to the lack of a CBM, was 
used as a negative control[9]. Amylose beads were incubated with 0.25-5µg protein for 
30 min then pelleted by centrifugation. Protein in supernatant and pellet fractions were 
detected using Western anaylsis. Gg-laforin bound amylose to the same extent as Hs- 
laforin, while VHR did not bind and remained in the supernatant (Fig. 7A). 
 
Gg-laforin monomer has phosphatase activity comparable to Hs-laforin 
To determine if Gg-laforin is a phosphatase, Gg-laforin was assayed against the 
artificial substrate pNPP at multiple pH units from 5.0-8.0. In this assay and in the next 
one, a mutant Gg-laforin was utilized as a negative control. Dephosphorylation occurs 
via a cysteine residue (Cys253) that performs a nucleophillic attack of the substrate 
phosphate. Mutation of this cysteine to a serine abolishes phosphatase activity, but does 
not perturb the tertiary structure of the phosphatase. Gg-laforin displayed similar specific 
activity to Hs-laforin and also preferred the lower pH (Fig. 7B). Hs-laforin has been 
shown to bind and dephosphorylate glycogen and amylopectin, a characteristic unique to 
glucan phosphatases[9, 10].  We investigated the ability of Gg-laforin to dephosphorylate 
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Figure 6. A. SUMO-His6-tagged Gg-Laforin was purified first using immobilized metal affinity chromatography, 
and then passed over a a HiLoad 16/60 Superdex 200 size exclusion column. B. The monomer fraction was 
collected, concentrated and passed over the same column, and the single peak indicates that it remained 
monomeric. C. Samples were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue dye: (U) 
uninduced E. coli cells; (I) E. coli cells after expression was induced; (P) insoluble fraction after induction; (S) 
soluble fraction after induction; (E) IMAC eluate; and (S200) monomer fraction from S200 collections. 20 µg of 
total protein was loaded per lane. SUMO-HIS6-Gg-laforin  runs as a 50kDa species until the removal of the 14 kDa 
SUMO-tag prior to the S200 step. Gg-laforin is 36 kDa, the expected size of the laforin monomer. D. Dynamic 
light scattering was performed on a 1 mg/ml sample of S200-purified Gg-laforin monomer using the Protein 
Solutions DynaPro-99 system. DLS histogram displays the size distribution of particles in solution. A single 
species was detected with hydrodynamic radius of 2.68nm, that corresponds to a molecular weight of 31.6±14.5 
kDa. 
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amylopectin, which contains detectable amounts of phosphate, using a malachite green 
assay. Gg-laforin possesses slightly higher specific activity against phosphorylated 
amylopectin to Hs-laforin, but appears to prefer a similar pH to Hs-laforin (Fig. 7C). 
These results demonstrate that Gg-laforin is an active phosphatase with acitivity levels 
similar to Hs-laforin. Furthermore, Gg-laforin is also able to bind and dephosphorylate 
amylopectin. Thus, Gg-laforin has the same biochemical characteristics as Hs-laforin, yet 
is more soluble when purified using a bacterial expression system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A. His-tagged proteins were 
incubated with amylose beads for 30 min at 
4°C, and then amylose beads were pelleted 
by centrifugaton. Protein input (I), 
supernatant (S) and pellet (P) were separated 
by SDS-PAGE  and visualized by Western 
analysis. B. Specific activity of Gg-laforin 
and Hs-laforin was quantified using 50mM 
pNPP as substrate in 0.1 M sodium acetate, 
0.05 M bis-Tris, 0.05 M Tris-HCl, and 2 mM 
DTT. Assays were performed with 200-400 
ng enzyme for 2 min. C. Glucan phosphatase 
activity was measured by malachite green 
assays. Buffer conditions were the same as 
described for pNPP; reactions were 
performed with 45 µg amylopectin and 100 
ng enzyme for 2-5 min. 
 
 
 
 
Conclusions 
 
Human laforin has proven to be a difficult protein to express in recombinant 
systems. These difficulties are highlighted by previous reports that Hs-laforin must be 
purified from inclusion bodies in E. coli[15, 22]. Although our lab has been able to purify 
laforin without denaturation and refolding steps, recombinant Hs-laforin has proved a 
difficult protein to manipulate in vitro due to its tendency to aggregrate, denature and 
precipitate. Therefore, we sought a laforin ortholog with greater solubility and stability, 
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yet with similar in vitro characteristics to Hs-laforin. This protein would be a more 
conducive target for crystallography studies. We have demonstrated that Gg-laforin can 
be purified without the use of denaturation and refolding steps, have established a 
purification protocol that includes minimal additives to improve solubility, and have 
characterized the biochemical properties of Gg-laforin. We have shown that Gg-laforin is 
present mainly as a monomer, remains monomeric, and retains phosphatase and 
carbohydrate-binding activity as a monomer in the absence of a fusion tag. Monomeric 
Gg-laforin has robust phosphatase activity against the artificial substrate pNPP and also 
the biologically relevant substrate amylopectin, similar to the activity of Hs-laforin as 
previously described[9, 17]. 
Importantly, HIS6-SUMO-Gg-laforin is expressed as soluble protein in E. coli, 
remains soluble after cleavage of the fusion protein during experimental manipulation, 
and possesses both phosphatase and carbohydrate-binding capabilities. Consequently, 
Gg-laforin is an appropriate model for Hs-laforin in crystallographic analysis and 
structure-function studies. The characterization of Gg-laforin has provided an alternate 
route for obtaining the crystal structure of laforin, which may clarify the role of laforin in 
the metabolism of insoluble carbohydrates and the etiology of Lafora disease. 
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